NEW YORK (360Dx) – VolitionRx today announced the creation of its wholly owned US subsidiary, Volition America.

The subsidiary will be based in Austin, Texas. Jason Terrell, currently the CMO of Volition, will be the president and CEO of Volition America, where he will oversee the commercialization of Nu.Q cancer tests in the US. His focused will be on on implementing 510(k) and premarket approval trials for colorectal cancer, the Belgium-based firm said.

Scott Powell, now executive vice president of Volition will become vice president and CFO of the US subsidiary.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.